title: Differential Sensitivity to Crizotinib: Does EML4-ALK Fusion Variant Matter?
authors.affiliation: Massachusetts General Hospital Cancer Center, Boston, MA.
authors.forename: Jessica J
authors.initials: JJ
authors.lastname: Lin
authors.affiliation: Massachusetts General Hospital Cancer Center, Boston, MA ashaw1@mgh.harvard.edu.
authors.forename: Alice T
authors.initials: AT
authors.lastname: Shaw
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung; D000077547:Crizotinib; D006801:Humans; D008175:Lung Neoplasms; D015514:Oncogene Proteins, Fusion; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D020794:Receptor Protein-Tyrosine Kinases
chemical_list: C522504:EML4-ALK fusion protein, human; D015514:Oncogene Proteins, Fusion; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; D020794:Receptor Protein-Tyrosine Kinases